Literature DB >> 8069185

Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers.

T Nakahata1, N Okumura.   

Abstract

This review summarizes the changes in cell surface antigen expression during proliferation and differentiation of human erythroid progenitors. The content is based on our experimental data obtained from complement-mediated cytotoxicity assays against hematopoietic progenitors and a combined technique of sequential micromanipulations of paired daughter cells derived from erythroid burst-forming units (BFU-E) and immunostaining with a panel of monoclonal antibodies, as well as from current information. BFU-E has CD34, CD41a (platelet glycoprotein[GP]IIb/IIIa) and CD41b(GPIIb) antigens. Paired daughter cells derived from BFU-E have CD41a, CD41b, CD71 (transferrin receptor) and HLA-DR antigens, but not CD34 or CD33 antigen. The CD36 antigen (thrombospondin receptor or GPIV) is first expressed on the cells after 5 days of culture, in agreement with the report that the anti-CD36 positive fraction contained a greater part of the erythroid colony-forming units (CFU-E). The blood group A antigen is first expressed on cells from aggregates derived from BFU-E after 5 days of culture. Glycophorin A is expressed on cell surface after 7 days of culture when proerythroblasts first appear. Hemoglobin alpha is expressed after 8 days of culture and coincides with the first appearance of basophilic erythroblasts. This review provides useful information on the identification of leukemic cells from poorly differentiated acute leukemias such as early erythroblastic leukemia and acute megakaryoblastic leukemia, and is useful in the understanding of the commitment and differentiation of erythroid and megakaryocytic progenitors in normal hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8069185     DOI: 10.3109/10428199409049629

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

Review 1.  Historical review: megakaryopoiesis and thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

Review 2.  Improving Quality and Potency Testing for Umbilical Cord Blood: A New Perspective.

Authors:  Ivan N Rich
Journal:  Stem Cells Transl Med       Date:  2015-07-09       Impact factor: 6.940

3.  A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor.

Authors:  Eyayu Belay; Chris P Miller; Amanda N Kortum; Beverly Torok-Storb; C Anthony Blau; David W Emery
Journal:  Blood       Date:  2014-10-24       Impact factor: 22.113

Review 4.  Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Authors:  Antonia Rotolo; Anastasios Karadimitris; Marco Ruella
Journal:  Leuk Lymphoma       Date:  2017-11-22

5.  Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.

Authors:  Denise M Crooks; Gustavo Pacheco-Rodriguez; Rosamma M DeCastro; J Philip McCoy; Ji-an Wang; Fumiyuki Kumaki; Thomas Darling; Joel Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-06       Impact factor: 11.205

6.  The platelet: life on the razor's edge between hemorrhage and thrombosis.

Authors:  Barry S Coller
Journal:  Transfusion       Date:  2014-08-05       Impact factor: 3.157

7.  Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence.

Authors:  Claudia Filippone; Rauli Franssila; Arun Kumar; Leena Saikko; Panu E Kovanen; Maria Söderlund-Venermo; Klaus Hedman
Journal:  PLoS One       Date:  2010-03-02       Impact factor: 3.240

8.  Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication.

Authors:  Susan Wong; Ning Zhi; Claudia Filippone; Keyvan Keyvanfar; Sachiko Kajigaya; Kevin E Brown; Neal S Young
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

9.  Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.

Authors:  Quan-shun Wang; Yao Wang; Hai-yan Lv; Qing-wang Han; Hui Fan; Bo Guo; Li-li Wang; Wei-dong Han
Journal:  Mol Ther       Date:  2014-09-01       Impact factor: 11.454

10.  Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.

Authors:  Eiman Hussein; Todd DeFor; John E Wagner; Darin Sumstad; Claudio G Brunstein; David H McKenna
Journal:  Transfusion       Date:  2019-11-22       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.